Xeris Biopharma Announces First Participant Dosed In A Phase 2 Clinical Study Of Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) In Patients With Hypothyroidism
Portfolio Pulse from Bill Haddad
Xeris Biopharma has announced the dosing of the first participant in a Phase 2 clinical study of its investigational subcutaneous levothyroxine (XP-8121) for patients with hypothyroidism.
June 21, 2023 | 11:11 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Xeris Biopharma's stock may be positively impacted by the initiation of the Phase 2 clinical study of its investigational subcutaneous levothyroxine (XP-8121) for hypothyroidism patients.
The initiation of the Phase 2 clinical study indicates progress in the development of Xeris Biopharma's investigational subcutaneous levothyroxine (XP-8121). This progress may be seen as a positive sign by investors, potentially leading to an increase in the stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100